Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis (OA) has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP). Flexion's Chief Medical Officer Neil Bodick, M.D., Ph.D., will present the data during the meeting on October 29, 2013, in San Diego, California.
Information for the oral presentation session is highlighted below:
(Abstract #2668): Tuesday, October 29, 2013, 2:30 PM PST "A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, an Intra-Articular (IA) Sustained-Release Formulation of Triamcinolone Acetonide (TCA), to an Approved Injectable Suspension of TCA in Patients with Osteoarthritis (OA) of the Knee," [Osteoarthritis I: Therapeutics in Osteoarthritis] [Hilton 306-A]
"We are excited to present these Phase 2b data since they show magnitude of pain relief with FX006 that is among the largest observed in clinical trials," said Michael Clayman, M.D., Flexion Therapeutics CEO. "FX006 was also well tolerated and overall the data indicate that FX006 has the potential to provide a more effective treatment option than current immediate release steroids."